Advertisement
Advertisement
VTGN
Vistagen Therapeutics, Inc. Common Stock
0.29
USDSponsored
0.00
+1.34%
Aug 07, 15:59 UTC -4
Closed
After-Market
0.29
0.00
-0.56%
VTGN Earnings Reports
Positive Surprise Ratio
VTGN beat 20 of 39 last estimates.
51%
Next Report
Date of Next Report
Nov 11, 2026
Estimate for Q2 27 (Revenue/ EPS)
$154.53K
/-$0.27
Implied change from Q1 27 (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
-40.10%
/-50.00%
Vistagen Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, VTGN reported earnings of -- USD per share (EPS) for Q1 27, -- the estimate of -0.37 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 255.00 thousand, with a --% difference.
Looking ahead to Q2 27, 6 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 154.53 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
FAQ
What were Vistagen Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2027?
For Q1 2027, Vistagen Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Vistagen Therapeutics, Inc. Common Stock's Q1 2027 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Vistagen Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for Vistagen Therapeutics, Inc. Common Stock's next earnings report?
Based on 6
analysts, Vistagen Therapeutics, Inc. Common Stock is expected to report EPS of -$0.27 and revenue of $154.53K for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement